Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.22.1
Schedule of Accrued Expenses (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Payroll and incentives $ 482,000 $ 1,343,000
General and administrative expenses 302,000 195,000
Research and development expenses 355,000 381,000
Deferred revenue and other deferred liabilities [1] 702,000 932,000
Total $ 1,840,748 $ 2,850,888
[1] At March 31, 2022, approximately $669 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech Agreement. At December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech feasibility study agreement.